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ABSTRAK
Latar belakang: terapi eritropoietin sangat penting pada pasien penyakit ginjal kronik (PGK) untuk 
mempertahankan kadar Hb tetap optimal. Renogen adalah suatu epoetin-α biosimilar, sedangkan Eprex adalah 
epoetin-α inovator. Penelitian ini bertujuan membandingkan efikasi dan toleransi Renogen dengan Eprex untuk 
anemia akibat PGK. Metode: Renogen dan Eprex dibandingkan dalam studi random (2:1), tidak tersamar, 
selama 8 minggu, didahului dengan fase penyesuaian selama 4 minggu, pada pasien anemia akibat PGK yang 
menjalani hemodialisis di RSUPN Cipto Mangunkusumo, Jakarta, dari Juni 2017 sampai dengan Oktober 2018. 
Hasil: sejumlah 45 pasien (31 mendapat EPO biosimilar dan 14 menerima EPO inovator) diikutsertakan dalam 
studi. Pada awalnya, rerata (SD) kadar Hb berturut-turut 10,9 (0,74) g/dL dan 10,9 (0,61) g/dL dalam kelompok 
EPO biosimilar dan EPO inovator. Di akhir studi (8 minggu), rerata (SD) kadar Hb berturut-turut 10,5 (1,28) g/
dL dan 11,0 (1,13) g/dL dalam kelompok EPO biosimilar dan EPO inovator.  Proporsi pasien dengan kadar Hb 
yang bertahan dalam kisaran target (>10 g/dL) selama 8 minggu adalah 58,1% dalam kelompok EPO biosimilar 
dan 71,4% dalam kelompok EPO inovator (p=0,60; TB). Tidak ada perbedaan bermakna dalam dosis epoetin dari 
EPO biosimilar dan EPO inovator yang digunakan, dan tidak ada efek samping yang terkait dengan obat pada 
kedua kelompok. Kesimpulan: kadar Hb >10 g/dL dapat dipertahankan selama 8 minggu pengobatan dengan 
EPO inovator  maupun EPO biosimilar (lebih konsisten dengan EPO inovator dan lebih berfluktuasi dengan 
EPO biosimilar), dengan dosis epoetin yang sama dan tidak ada efek samping yang berkaitan dengan obat.
Kata kunci: anemia ginjal, eritropoietin, biosimilar, hemodialisa.
ABSTRACT
Background: treatment of erythropoietin (EPO) is essential in chronic kidney disease (CKD) patients to 
maintain optimal hemoglobin (Hb) level. Renogen is a biosimilar epoetin-α, and Eprex is the originator epoetin-α. 
This study aimed to compare the efficacy and tolerance of Renogen with Eprex in CKD anemia. Methods: 
Renogen and Eprex were compared in a randomized (2:1), open-label study for 8 weeks, proceeded by 4 weeks 
adjustment (maintenance) phase, in anemic CKD patients undergoing HD in Cipto Mangunkusumo General 
Hospital, Jakarta, from June 2017 to October 2018. Results: a total of 45 patients (31 received biosimilar 
EPO and 14 received originator EPO) were included in the study.  At baseline, mean (SD) Hb levels were 
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10.9 (0.74) g/dL and 10.9 (0.61) g/dL in biosimilar and originator EPO groups, respectively. At end of study 
(8 weeks), mean (SD) Hb levels were 10.5 (1.28) g/dL and 11.0 (1.13) g/dL in biosimilar EPO and originator 
EPO groups, respectively.  The proportion of patients with Hb levels maintained within the target range (>10 
g/dL) during 8 weeks randomization phase were 58.1% and 71.4% in biosimilar EPO and originator EPO, 
respectively (p=0.60; NS). There were no significant difference in epoetin dose between the 2 groups, and there 
was no drug-related adverse event in either group. Conclusion: Hb level at >10 g/dL could be maintained for 
8 weeks of treatment with both originator and biosimilar EPO (more consistent with originator EPO and more 
fluctuations with biosimilar EPO), with similar epoetin dose and no drug-related adverse event.
Keywords: renal anemia, erythropoietin, biosimilar, hemodialysis.
INTRODUCTION
Anemia in chronic kidney disease (CKD) 
patients is due to failure of the kidneys to produce 
sufficient endogenous erythropoietin (epoetin or 
EPO) to stimulate the bone marrow to produce 
RBCs. CKD anemia is corrected and maintained 
with human recombinant erythropoietin (rHu-
EPO) which is available since the early 1990s. 
Several erythropoiesis-stimulating agents 
(ESAs) are now available, including epoetin a 
and b, darbepoetin a and the biosimilars.
Treatment with erythropoietin is absolutely 
necessary in patients with CKD to maintain 
quality of life by increasing the hemoglobin 
level to reach the target of >10 g/dL. Eprex  is 
the first rHuEPO (epoetin) in the world and has 
been shown to increase hemoglobin in CKD 
patients. Eprex, an EPO a, has been proven for 
its ability and safety in CKD patients. However, 
with respect to the price which is quite expensive, 
biosimilar products with the same ability are 
created, with an affordable price. Beiraghdar 
et al. concluded from their research comparing 
a biosimilar epoetin-a namely Pastopoetin to 
Eprex, that both products provided comparable 
results.1 Harzallah et al.2 conducted a study on a 
locally produced biosimilar epoetin a and found 
comparable results with the epoetin a produced 
by foreign laboratories. Based on this evidence, 
a study of a biosimilar epoetin a, Renogen, was 
carried out in anemic hemodialysis (HD) patients 
at Cipto Mangunkusumo Hospital (RSCM), 
Jakarta. The aim of this study was to assess the 
efficacy and tolerance of the biosimilar EPO 
(Renogen) in the management of anemia in CKD 
in Indonesia.
METHODS
A study on anemic CKD patients undergoing 
hemodialysis  was conducted in Cipto 
Mangunkusumo Hospital, Jakarta, from June 
2017 to October 2018.  We compared a biosimilar 
epoetin a, Renogen, with the originator epoetin 
a, Eprex, in a randomized (2:1), open-label study 
for 8 weeks. The number of samples was 45; 
30 subjects received Renogen and 15 subjects 
received Eprex. Since this was a preliminary 
study, sample size was not calculated, and a ratio 
of 2 to 1 was decided by the investigators.
This study has been approved by the Ethics 
Committee of Faculty of Medicine Universitas 
Indonesia, reference number 1102/UN2.F1/
ETIK/2015.
Subjects
Anemic CKD patients on routine HD twice 
weekly for at least 6 months; hemoglobin level 
between 10-11 g/dL for a minimum of 12 weeks; 
a stable dose of erythropoietin IV for at least 8 
weeks with a maximal weekly dose of 200 IU/
kg body weight (definition of stable dose is a 
change in dose of less than 25% per week, without 
changes in injection frequency); serum ferritin 
>200 ng/mL or transferrin saturation >20%; male 
or female patients, aged between 18-75 years 
(female patients in post-menopausal period or 
using adequate contraception were acceptable); 
patients agreed to participate in the study (has 
signed the informed consent form). Excluded 
from the study were resistant to EPO; failed to 
achieve Hb target level despite an adequate level 
of transferrin saturation and after being given 
500 IU/kg/week IV rhu-EPO for 4 months; 
hypersensitivity to erythropoietin; pregnancy, 
planning to get pregnant, or in a lactation program; 
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uncontrolled hypertension (>170/100 mmHg); 
malnutrition (serum albumin <30 g/L); patients 
on waiting list for kidney transplantation; under 
treatment of immunosuppressants (including 
corticosteroids) or androgens within 3 months 
before screening; post major surgery 3 months 
before screening (excluding vascular surgery); 
severe heart disease (MI, PCI, CABG) or 
severe cerebrovascular disease 6 months before 
screening; Heart Failure Class III/IV of NYHA 
classification or unstable angina; bleeding that 
requires transfusion within 3 months before 
screening or during screening period; non-renal 
anemia such as hemoglobinopathy, sickle cell 
anemia, hemolytic anemia, aplastic anemia, 
myelodysplastic syndrome, hematological 
malignancy, and myeloma; platelet count 
>500,000/mm3; any history of malignancy 5 
years before screening; grandmal’s seizures for 
6 months before screening; acute inflammatory 
diseases such as SLE, rheumatoid arthritis; acute 
or chronic active infection;  SGOT/SGPT ≥3 times 
ULN; HIV or Hepatitis B infection; history of drug 
or alcohol abuse; participating in other clinical 
trials within 3 months prior to screening; inability 
to follow study instruction and procedure.
This study was conducted in 2 phases: Phase 
I was the adjustment (maintenance) phase for 4 
weeks. Patients who have been stable on any 
erythropoietin previously, were changed to the 
originator EPO with a dose of 150-200 IU/kg 
BW/week, given intravenously to maintain Hb of 
10-11 g/dL for 4 weeks. If during the originator 
EPO administration, the Hb level was >11 g/dL, 
the originator EPO dose was reduced, and when 
the Hb level was <10 g/dL, the originator EPO 
dose was increased. The maximum dose of the 
originator EPO for 4 weeks was 200 IU x 60 kg 
x 4 weeks = 48.000 IU.
Phase II was the randomization phase for 
8 weeks. Patients were randomized into two 
groups, one group of patients received the 
originator EPO  and the other group of patients 
received the biosimilar EPO. The maximum dose 
of the originator EPO or the biosimilar EPO was 
200 IU x 60 kg x 8 weeks = 96.000 IU.
Other drugs given were Fe sucrose 100 
mg IV once a month, and CaCO3 equivalent to 
elemental Ca 500 mg 3 times a day with meals. 
Drugs that should not be used during the study 
was corticosteroids.
The primary endpoint was the percentage of 
patients with Hb level maintained within the target 
range (>10 g/dL) during the randomization phase. 
These data were analyzed using X2 statistics 
between the biosimilar and the originator groups.
Laboratory Tests
These tests were performed during patient 
screening, and at weeks 4, 8, and 12, i.e: 
routine hematology: leukocytes, neutrophils, 
lymphocytes, hemoglobin, platelets, hematocrit, 
MCV, MCH, MCHC, and reticulocytes; liver 
function tests: bilirubin, SGOT, and SGPT; kidney 
function tests: urea and creatinine; electrolytes: 
Na, K, and Cl; iron metabolism: serum iron, 
serum ferritin, transferrin saturation and total iron 
binding capacity (TIBC). ECG examination was 
done at screening, week 4, and week 12.
Patient Discontinuation
The patient was discontinued if any of 
the following occurred: at the request of the 
patient; HD regimen changed; Hb levels 
decreased ≥20% during the study compared to 
baseline value or <8 g/dL at 2 measurements 
within 1 week; uncontrolled hypertension; 
uncooperative patient; severe bleeding requiring 
blood transfusion; patients requiring surgery 
during the study; an emergency condition.
RESULTS
At the adjustment (maintenance) phase, 
there were 80 subjects participating. In the initial 
randomization phase, the number of subject was 
47, 16 subjects in the originator EPO group and 
31 subjects in the biosimilar EPO group. Before 
the first visit after randomization, one subject in 
the originator EPO group was lost to follow-up 
and another patient was excluded from the study 
because it did not meet the study requirements. 
Three subjects in the biosimilar EPO group 
were excluded during the randomization phase 
(during the last weeks of study or on visit 7 and 
8) because the Hb level dropped >20%. But the 
three drop out subjects in the biosimilar EPO 
group were analyzed in the baseline demography 
data. The number of subjects who completed the 
study were 14 in the originator EPO group and 
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28 in the biosimilar EPO group (Figure 1). The 
characteristics of the study population at baseline 
are shown in Table 1.
At baseline, the median Hb in the biosimilar 
EPO and the originator EPO groups were 10.8 
g/dL and 10.9 g/dL, respectively. At 2 weeks of 
randomization, the median Hb for the biosimilar 
EPO group was 11.2 g/dL, and for the originator 
EPO group was 11.3 g/dL. At 8th week of 
randomization, the median Hb for the biosimilar 
EPO and the originator EPO groups were Hb 
11.0 g/dL and 10.8 g/dL, respectively. Figure 
2 showed the trend of Hb during the study. 
Statistical analysis (t-test) comparing Hb values at 
different weeks of treatment showed no significant 
differences between the biosimilar EPO group and 
the originator EPO group (Table 2). Proportions 
of subjects within Hb levels within target range 
(≥10 g/dL) during randomization phase were also 
not significantly different between the 2 groups 
(Table 3). Data on safety analysis during the study 
are shown in Table 5.
Screening and maintenance phase
N=80
Randomization phase
N=47
Originator EPO treatment group
n=16
Biosimilar EPO treatment group
n=31
Withdrawn
n=2
Completed trial
n=14
Withdrawn
n=3
Completed trial
n=28
Figure 1. Flowchart of subjects included in the study.
Table 1. Demographics and other baseline characteristics of subjects enrolled in the study
Variables The Originator EPO (N = 14) The Biosimilar EPO (N = 31)
Male, n (%) 6 (42.9%) 16 (51.6%)
Age (years), mean (SD) 46.6 (12.90) 45.6 (12.57)
Body weight (kg), mean (SD) 57.8 (13.37) 57.4 (10.91)
Comorbidities (%)
 - Diabetes mellitus - 3 (9.6%)
 - Hypertension 4 (28.6%) 19 (59.4%)
 - Heart disease 1 (1.7%) 3 (9.6%)
 - Stroke 1 (1.7%) -
 - Hyperthyroid 1 (7.1%) -
 - Hepatitis C 1 (7.1%) 2 (6.5%)
 - Lupus 1 (1.7%) -
Systolic blood pressure (mmHg), mean (SD) 130.4 (19.51) 140.5 (18.29)
Diastolic blood pressure (mmHg), mean (SD) 75.9 (9.69) 78.0 (14.00)
Hemoglobin (g/dL), mean (SD) 10.9 (0.61) 10.9 (0.74)
Serum iron (mg/dL), mean (SD) 60.9 (23.51) 59.1 (19.24)
Ferritin serum (ng/dL), mean (SD) 338.7 (315.61) 595.2 (696.11)
Total iron binding capacity (mg/dL), mean (SD) 229.2 (49.12) 209.2 (38.00)
Transferrin saturation (%), mean (SD) 26.2 (6.59%) 28.7 (9.50%)
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Table 2. Hemoglobin levels every two weeks of treatment with the biosimilar EPO and the originator EPO
Hemoglobin (g/dL) Baseline
Randomization Phase
2 weeks 4 weeks 6 weeks 8 weeks
THE BIOSIMILAR EPO n = 31 n = 31 n = 31 n = 31 n = 28
Mean (SD) 10.9 (0.74) 11.3 (1.21) 11.1 (1.09) 11.0 (1.60) 10.5 (1.28)
Median 10.8 11.2 11.2 11.2 11.0
Range 10.0 – 12.7 8.8 – 15.2 9.2 – 14.9 7.4 – 15.4 6.9 – 12.0
THE ORIGINATOR EPO n = 14 n = 14 n = 14 n = 14 n = 14
Mean (SD) 10.9 (0.61) 11.2 (0.96) 11.3 (1.33) 11.5 (0.98) 11.0 (1.13)
Median 10.9 11.3 11.4 11.6 10.8
Range 10.0 – 12.0 9.7 – 12.7 9.6 – 14.9 9.2 – 12.7 9.4 – 13.1
Statistic test * t = 0.160 t = 0.358 t = 0.581 t = 1.204 t = 1.166
p value 0.87 (NS) 0.72 (NS) 0.57 (NS) 0.24 (NS) 0.25 (NS)
*t-test (t); NS = Not significantly different
Figure 2. Mean Hb levels during 8 weeks of treatment with the originator EPO and the biosimilar EPO.
Table 3. Proportion of subjects (in the biosimilar EPO and the originator EPO groups) with Hb levels maintained within 
the target range (>10 g/dL) during the randomization phase
Group
Number (%) of subjects with Hb levels
Success*
(Hb ≥ 10 g/dL)
Failure** 
(Hb < 10 g/dL)
Total
The biosimilar EPO 18 (58.1%) 13 (41.9%) 31 (100 %)
The originator EPO 10 (71.4%) 4 (28.6%) 14 (100%)
Total 28 (62.2%) 17 (37.8%) 45 (100%)
Statistical test:
X2 test 0.275
p value 0.6 (NS)
* Hb was consistent at >10 g/dL at each visit (every 2 weeks) during 8 weeks of treatment                    
**Hb was dropped below 10 g/dL at >1 visit during 8 weeks of treatment
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Table 4. Epoetin doses (IU) of the biosimilar EPO and the originator EPO at each visit during 8 weeks of treatment
Drugs Baseline
Randomization Phase
2 weeks 4 weeks 6 weeks
THE BIOSIMILAR 
EPO n = 31 n = 31 n = 31 n = 31
 - Mean 4645.2 4774.2 4516.1 4516.1
 - Median 4000 4000 4000 4000
 - Range 4000 - 6000 4000 - 6000 4000 - 6000 4000 - 6000
THE ORIGINATOR 
EPO n = 14 n = 14 n = 14 n = 14
 - Mean 4857.1 4571.4 4285.7 4428.6
 - Median 4000 4000 4000 4000
 - Range 4000 - 6000 4000 - 6000 4000 - 6000 4000 - 6000
Mann-Whitney U
 - test (Z) 0.680 0.508 0.851 0.313
 - p value p = 0.50 (NS) p = 0.61 (NS) p = 0.40 (NS) p = 0.75 (NS)
Table 5. Subjects with adverse event and serious adverse event during 8 weeks’ treatment of the biosimilar EPO and the 
originator EPO
Description The biosimilar EPO (n = 32) The originator EPO (n = 15)
Subjects for safety analysis 32 (100%) 15 (100%)
Total subject with AE - -
Total subject with SAE 1 (3%) -
Serious adverse event list
Herpes (non drug-related) 1 (3%) -
The erythropoietin doses were not significantly 
different between the biosimilar EPO and the 
originator EPO groups throughout the study 
(Table 4).
DISCUSSION
Our study showed that the biosimilar EPO 
was statistically equivalent to the originator 
EPO  in terms of Hb response on treatment. 
The biosimilar EPO, Renogen, is extracted 
from Chinese hamster ovary (CHO) cell 
cultures into which the human erythropoietin 
gene has been introduced by recombinant 
DNA technology. Renogen, a 165 amino acid 
glycoprotein, has a molecular weight of about 
34KD. It has the same physiological functions 
as natural human erythropoietin, and can 
stimulate the differentiation and multiplication 
of committed erythropoietic progenitors in the 
bone marrow.3 The use of rHuEPO has obviated 
the need for blood transfusion in CKD patients, 
thereby reducing the adverse events commonly 
associated with such conventional therapies.4-7 
In our study, the treatment of biosimilar EPO 
to CKD patients undergoing hemodialysis was 
effective in maintaining the hemoglobin levels 
within the recommended hemoglobin target 
for HD patients, although the Hb level can be 
maintained more consistently in the originator 
EPO  group.
In a multicenter, prospective study on 24 
cadaveric kidney transplant patients, Baltar et al.8 
administered rHuEPO to patients with chronic 
allograft nephropathy at a subcutaneous dose of 
2000 IU/kg once a week. Approximately 48% 
of patients were reported to reach target levels 
of Hb (11 g/dL) after 4 months of treatment.8 In 
the present study, mean Hb level increased and 
more than 50% of patients reached normal Hb 
values after 8 weeks of erythropoietin therapy 
(58.1% and 71.4% in the biosimilar EPO and 
the originator EPO groups, respectively), with 
no significant difference in dose between the 
two groups (median dose of epoetin was 4000 
Ni Made Hustrini                                                                                                            Acta Med Indones-Indones J Intern Med
236
IU twice weekly in both groups). The real-world 
effectiveness and safety of a biosimilar epoetin 
alfa (HX575) in HD patients was also assessed 
in a large prospective, observational study for 
up to 24 months follow up in 114 centers in 10 
European countries.9 The study confirmed the 
real-world effectiveness and safety profile of IV 
biosimilar HX575. They found that at baseline, 
mean (SD) baseline Hb was 11.09 (1.14) g/dL 
with HX575 dose of 106.5 (78.7) IU/kg/week; at 
month 24, Hb was 11.25 (1.19) g/dL with HX575 
dose of 113.0 (102.5) IU/ kg/week. Variations in 
mean HX575 dose and Hb over the study were 
not statistically significant.9
The biosimilar EPO was well tolerated and 
its safety profile was comparable to the originator 
EPO  in terms of the frequency of adverse events. 
We have only one serious adverse event that was 
not drug-related (i.e. Herpes, 1/32, 3%) in the 
biosimilar EPO group. This result was similar to 
the results of a large observational prospective 
multicenter study by Stoppa et al. in 2018.10 They 
found no difference between the two cohorts 
of users (originator versus biosimilar epoetin 
a) with regard to any kind of adverse events, 
even after adjusting for confounding factors: 
1.0 (95% confidence interval [CI] 0.7–1.3) for 
any outcome; 1.1 (95% CI 0.7–1.8) for problems 
related to dialysis device; 0.9 (95% CI 0.6–1.5) 
for cardio- and cerebrovascular conditions; 0.9 
(95% CI 0.6–1.5) for infections.8,10 Study by 
London et al.9 also reported the safety of HX575 
(a biosimiar epoetin α) was comparable to the 
reference epoetin a. They found 140 patients 
(6.7%) experienced ≥ 1 adverse events; of these, 
19 events (16 patients, 0.8%) were related to 
HX575 treatment, 148 events (108 patients, 
5.2%) were reported as serious, including 12 
events in 11 patients (0.5%) stated to be treatment 
related. No cases of anti-epoetin antibodies or 
pure red cell aplasia were reported.9
To our knowledge, this study was the first 
randomized controlled study on a biosimilar 
epoetin α in Indonesia. The limitation of 
this study was the small number of patients 
participated in the study. A large study with the 
same design will be expected to confirm the 
results of the present study.
CONCLUSION
The mean Hb level could be maintained at 
>10 g/dL every 2 weeks for 8 weeks of treatment 
with both the originator EPO and the biosimilar 
EPO, more consistent (stable) with the originator 
EPO, and more fluctuating with the biosimilar 
EPO. Epoietin dose did not differ significantly 
between the two groups. There was no drug-
related adverse event in either group.
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